Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis

Authors
Publication date
1 August 2020
Publisher
'Wiley'
Doi

    Abstract

    International audienc

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Hal-Diderot

      redirect
      oaioai:HAL:hal-03287285v1
      Last time updated on 11/05/2022

      HAL Descartes

      redirect
      oaioai:HAL:hal-03287285v1
      Last time updated on 17/08/2022

      HAL-HCL

      redirect
      oaioai:HAL:hal-03287285v1
      Last time updated on 03/12/2021

      HAL-UNILIM

      redirect
      oaioai:HAL:hal-03287285v1
      Last time updated on 03/12/2021